Friedl-Naderer Johanna 4
4 · Dyne Therapeutics, Inc. · Filed Mar 13, 2025
Insider Transaction Report
Form 4
Friedl-Naderer Johanna
Chief Commercial Officer
Transactions
- Sale
Common Stock
2025-03-13$12.12/sh−143$1,733→ 96,057 total
Footnotes (2)
- [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- [F2]Includes 93,838 unvested RSUs.